用romiplostim进行免疫调节作为初级免疫血小板缺血的二线策略:iROM研究
Alexandra Schifferli1, Axel Rüfer2, Alicia Rovo3
1Department of Hematology/Oncology, University Children's Hospital Basel, Basel, Switzerland.
British journal of haematology
|September 22, 2023
概括
血栓形成素受体激动剂 (TPO-RAs) 可能在免疫血栓缩 (ITP) 中恢复免疫耐受性. 在iROM研究中发现了罗米普洛斯调节免疫细胞,在治疗后实现持续缓解的患者中,调节性T细胞数量更高.
科学领域:
- 免疫学 免疫学 免疫学
- 血液学 血液学 血液学
- 药理学 药理学是指药理学的学科.
背景情况:
- 初级免疫性血小板缺血 (ITP) 是一种自身免疫性疾病,其特征是血小板数量较低.
- 血栓形成素受体激动剂 (TPO-RAs) 用于增加血小板的产生.
- 在ITP中TPO-RAs的免疫调节作用尚未完全理解.
研究的目的:
- 为了研究romiplostim在ITP患者中的免疫调节作用.
- 评估免疫变化与治疗结束后持续缓解 (SROT) 之间的关系.
主要方法:
- 该iROM研究涉及13名ITP患者,他们接受了罗米普洛司姆治疗22周.
- 免疫学参数,血小板计数和临床结果被监测了52周.
- 二级终点包括SROT速率,罗米普洛斯蒂姆剂量和出血事件.
主要成果:
- 在13名患者中,有6名患者实现了SROT;七名患者复发.
- 患有SROT的患者有较低的罗米普洛司姆剂量和更强的血小板反应.
- 调节性T淋巴细胞 (Treg) 数量在所有患者中都增加,在SROT组中更高.
- 在SROT组中,干白素 (IL) -4,IL -9,IL -17F水平下降,而FOXP3,GATA3 mRNA和TGF-β在SROT组中增加.
结论:
- 罗米波洛斯蒂姆治疗对ITP患者的免疫系统进行调节.
- 血小板数量的快速增加可能对诱导免疫耐受性至关重要.
- 对自身免疫的早期干预可能会改善结果,这需要进一步的临床研究.
更多相关视频
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
186
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
186
Tumor Immunotherapy
551
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
551
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
164
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
164
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Myocarditis III: Medical Management
7
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
7
Inflammatory Bowel Disease IV: Pharmacological Management
145
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
145


